Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993133 | 0.83 | TSHR (0.45) | TLR2EPHX2LMNA | |
| SCHEMBL18782967 | 0.81 | PTGS1 (0.51) | TLR2 | |
| SCHEMBL18782966 | 0.77 | DNM1 (0.42) | LMNA | |
| SCHEMBL18783177 | 0.77 | ALDH1A1 (0.56) | — | |
| SCHEMBL19386446 | 0.76 | TLR2 (0.53) | ADRA1APRMT1TLR2PLA2G2AEPHX2 | |
| SCHEMBL19388373 | 0.76 | ADRA1A (0.53) | ADRA1APRMT1PLA2G4ATLR2PLA2G2A | |
| SCHEMBL19386447 | 0.76 | TLR2 (0.53) | ADRA1APRMT1TLR2PLA2G2AEPHX2 | |
| SCHEMBL19388372 | 0.76 | ADRA1A (0.53) | ADRA1APRMT1PLA2G4ATLR2PLA2G2A | |
| SCHEMBL2331154 | 0.75 | CYP2D6 (0.53) | ADRA1APRMT1PLA2G4AECE1ATM | |
| SCHEMBL4775556 | 0.75 | FFAR1 (0.57) | PLA2G4ATLR2PLA2G2AFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | ADRA1A 485/4885PRMT1 3357/4885PLA2G4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.